Rituximab

The addition of brentuximab vedotin to lenalidomide and rituximab extended OS among patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.

The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

In this video, Tycel Phillips, MD, discusses treatment options available to patients with DLBCL.

In this video, Tycel Phillips, MD, discusses challenges in diagnosing DLBCL.

SCOTTSDALE, Ariz. — Recent efforts in vasculitis research have seen both “exciting” and “frustrating” results, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.

In this video, Jason Westin, MD, discusses the results of the Smart Stop trial, presented at ASH Annual Meeting and Exposition.

An association with long-term complete remission was found in patients with pemphigus who used rituximab as first-line therapy, according to an extension study.

In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.